Maravai LifeSciences Holdings, Inc., a life sciences company, provides products that enable the development of drug therapies, vaccines, drug therapies, cell and gene therapies, and diagnostics North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin and Central America. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, and oligonucleotide therapy, as well as molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, CleanCap capping technology-based oligonucleotide building blocks, and custom enzyme development and manufacturing; and research products for labeling and detecting proteins in cells and tissue samples. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, and antibody-based products to detect impurities during the production of biopharmaceutical products. It serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. Maravai LifeSciences Holdings, Inc. was founded in 2014 and is headquartered in San Diego, California.

Maravai LifeSciences Holdings Inc.

In a report released today, Daniel Arias from Stifel Nicolaus maintained a Buy rating on Maravai Lifesciences Holdings, with a price target of $4.0...

Maravai Lifesciences Holdings (MRVI) Receives a Buy from Stifel Nicolaus

In a report released today, Matt Hewitt from Craig-Hallum reiterated a Buy rating on Maravai Lifesciences Holdings. The company’s shares opened tod...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	MRVI	$3.75	+9.65%	2.46M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	MRVI	$3.75	+9.6%	2.46M
3
4
5
6

MRVI

MRVI

Latest News for MRVI

Get Maravai LifeSciences Holdings Inc. Data in Excel

Get Maravai LifeSciences Holdings Inc. Data in Excel